Allison Butts, PharmD, BCOP

If SG plus pembrolizumab becomes approved in the first-line metastatic TNBC setting, many clinicians anticipate shifting practice patterns to favor this regimen, given its promising efficacy.

From a pharmacologic standpoint, the adverse events associated with sacituzumab govitecan (SG)—particularly neutropenia and diarrhea—are consistent with the mechanism of its payload.

New findings reveal a modest overall survival benefit of abemaciclib in early breast cancer, highlighting the importance of ongoing patient education and treatment strategies.

Panelists introduce key CDK4/6 inhibitor data from ESMO 2025, setting the stage for insightful discussions on pivotal clinical trials and questions.

In clinical practice, the approach to G-CSF use with sacituzumab govitecan (SG) is typically individualized based on patient-specific risk factors and prior tolerance.

This section compares the adverse-event patterns of SG plus pembrolizumab versus chemotherapy plus pembrolizumab, emphasizing differences in hematologic and non-hematologic toxicities that inform clinical monitoring.

This segment explains how ASCENT-04 assessed whether moving sacituzumab govitecan into the first-line setting with immunotherapy could improve outcomes for a population with historically limited options.

This segment summarizes the challenges of metastatic TNBC and highlights how current treatment decisions rely on biomarkers and evolving molecular profiling to guide a personalized therapeutic approach.

The FDA is modernizing its approach to drug development and optimization.